<DOC>
	<DOCNO>NCT01789242</DOCNO>
	<brief_summary>This dose find study evaluate safety determine maximum tolerate dose carfilzomib patient previously treat systemic light-chain amyloidosis .</brief_summary>
	<brief_title>A Safety Study Carfilzomib Patients With Previously-Treated Systemic Light Chain Amyloidosis</brief_title>
	<detailed_description>This dose find study evaluate safety determine maximum tolerate dose carfilzomib patient previously treat systemic light-chain amyloidosis . The study also explore efficacy carfilzomib proteasome inhibitor-naive proteasome inhibitor-exposed patient include hematologic response , organ response , progression free survival , time next therapy .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Males female ≥ 18 year age Histologicallyproven AL amyloidosis , confirm positive Congo red stain green birefringence polarize light microscopy evidence measurable clonal disease require active treatment define : Patients must clonal disease measureable serum free light chain ( FreeliteTM ) assay : For doseescalation cohort : define elevation amyloidogenic ( i.e . clonal ) light chain abnormal free kappa : lambda ratio For dose expansion cohort : addition , must difference amyloidogenic ( i.e . clonal ) nonamyloidogenic light chain ( dFLC ) least 50mg/L ( 5mg/dL ) Relapsed ( progressed prior response ) refractory ( failed achieve least partial response ) least one prior therapy amyloidosis . Patients receive autologous stem cell transplant must least 3 month posttransplant recover acute transplantrelated toxicity . Patients unable tolerate least 1 cycle alkylating agent plus corticosteroid ( e.g . melphalan + dexamethasone ) alternative prior regimen severe adverse event ( e.g . hypersensitivity reaction ) may consider discussion study PI/Medical Monitor . Objective , measureable , symptomatic organ involvement , define one following : Kidney : albuminuria ≥ 500 mg/day 24hour urine specimen Heart : presence mean leave ventricular wall thickness echocardiogram great 12 mm absence hypertension valvular heart disease , unexplained low voltage ( &lt; 0.5 mV ) ECG , NTproBNP &gt; 332 ng/L absence impair renal function [ estimate glomerular filtration rate ( eGFR ) &lt; 45 mL/min ] Liver : hepatomegaly physical exam elevate alkaline phosphatase &gt; 1.5 x ULN GI Tract : biopsy show amyloid deposition along symptom GI bleed persistent diarrhea ( &gt; 4 loose stools/day ) Autonomic Peripheral Nervous System : defined orthostasis , symptom nausea dysgeusia , recurrent diarrhea constipation , abnormal sensory and/or motor finding neurologic exam , gastric atony gastric empty scan Note : Skin , lymph node , soft tissue involvement ; carpal tunnel syndrome ; bone marrow amyloid sole clinical manifestation amyloidosis sufficient inclusion . Amyloid cardiac biomarker stage I II disease Staging define NTproBNP troponin T cutoff &lt; 332 pg/mL &lt; 0.035 ng/mL , respectively , threshold : Stage I , threshold ; Stage II , either troponin NTproBNP ( ) threshold . If troponin T available local institution , troponin I may use , threshold &lt; 0.1 ng/mL.23 Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Clinical laboratory value specify within 14 day treatment : Absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L Hemoglobin ≥8 g/dL [ transfusion permit ] Platelet count ≥75.0 x 109/L Total bilirubin ≤ 2 x Upper Limit Normal ( ULN ) Alkaline phosphatase ≤ 5 x ULN Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3.5 x ULN CrCl ≥ 30 mL/min measure 24hour urine Screening ANC independent granulocyteand granulocyte/macrophage colony stimulate factor ( GCSF GMCSF ) support least 1 week pegylated GCSF least 2 week Screening platelet count independent platelet transfusion least 2 week Written inform consent accordance federal , local , institutional guideline Females childbearing potential must agree ongoing pregnancy test practice contraception abstain heterosexual intercourse Male patient must agree practice contraception abstain heterosexual intercourse Male patient must agree donate semen sperm Life expectancy ≥ 3 month Pregnant lactate female Major surgery within 21 day prior first dose Acute active infection require systemic antibiotic , antiviral , antifungal within 14 day prior first dose Treatment experimental drug within 28 day first dose Active Human Immunodeficiency Virus ( HIV ) hepatitis B C infection Bone marrow plasma cell ≥ 30 % clinical manifestation multiple myeloma , hypercalcemia lytic bone lesion Cardiac exclusion : Left ventricular ejection fraction ( LVEF ) &lt; 40 % Amyloid cardiac biomarker stage III disease , define NTproBNP ≥ 332 pg/mL troponin T ≥ 0.035 ng/mL . If troponin T available local institution , troponin I may use , cutoff ≥ 0.1 ng/mL New York Heart Association ( NYHA ) classification III IV heart failure ( see Appendix G ) despite medical management Unstable angina myocardial infarction within 6 month prior first dose Grade 2 3 atrioventricular ( AV ) block ( Mobitz type I permit ) sick sinus syndrome , unless subject pacemaker Known history sustain ( &gt; 30 second ) ventricular tachycardia cardiac syncope . Known history recurrent nonsustained ventricular tachycardia ( &gt; 3 beat ) despite antiarrhythmic therapy Supine systolic blood pressure &lt; 90 mm Hg , symptomatic orthostatic hypotension , decrease systolic blood pressure upon stand &gt; 20 mm Hg despite medical management ( e.g . midodrine , fludrocortisones ) Significant peripheral neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) within 14 day prior first dose Severe diarrhea ( ≥ grade 3 ) controllable medication require total parenteral nutrition History bleeding diathesis , know factor X deficiency ( level &lt; 20 % ) , requirement therapeutic anticoagulation warfarin Known allergy carfilzomib Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) Presence active malignancy exception nonmelanoma skin cancer , cervical cancer , treat earlystage prostate cancer provide prostatespecific antigen within normal limit , completely resect carcinoma situ Serious psychiatric medical condition could interfere treatment Contraindication require concomitant drug , include antiviral ( e.g . Valacyclovir ) Patients require program oral IV fluid hydration contraindicate , e.g . due severe preexist pulmonary , cardiac , renal impairment Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>